DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge
Open Access
- 15 September 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (37) , 15831-15836
- https://doi.org/10.1073/pnas.0902628106
Abstract
Optimized plasmid DNAs encoding the majority of SIVmac239 proteins and delivered by electroporation (EP) elicited strong immune responses in rhesus macaques. Vaccination decreased viremia in both the acute and chronic phases of infection after challenge with pathogenic SIVmac251. Two groups of macaques were vaccinated with DNA plasmids producing different antigen forms, “native” and “modified,” inducing distinct immune responses. Both groups showed significantly lower viremia during the acute phase of infection, whereas the group immunized with the native antigens showed better protection during the chronic phase (1.7 log decrease in virus load, P = 0.009). Both groups developed strong cellular and humoral responses against the DNA vaccine antigens, which included Gag, Pol, Env, Nef, and Tat. Vaccination induced both central memory and effector memory T cells that were maintained at the day of challenge, suggesting the potential for rapid mobilization upon virus challenge. The group receiving the native antigens developed higher and more durable anti-Env antibodies, including neutralizing antibodies at the day of challenge. These results demonstrate that DNA vaccination in the absence of any heterologous boost can provide protection from high viremia comparable to any other vaccine modalities tested in this macaque model.Keywords
This publication has 41 references indexed in Scilit:
- Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypesVaccine, 2009
- Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical DevelopmentsMolecular Therapy, 2009
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challengeNature Medicine, 2009
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- A Therapeutic SIV DNA Vaccine Elicits T-Cell Immune Responses, but No Sustained Control of Viremia in SIVmac239-Infected Rhesus MacaquesAIDS Research and Human Retroviruses, 2008
- Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate VaccineThe Journal of Infectious Diseases, 2006
- Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusVirology, 2006
- Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged MonkeysScience, 2006